Prognostic value of ABCG2 in moderately and poorly differentiated intrahepatic cholangiocarcinoma

Histopathology

Volumn 59, Issue 2, 2011, Pages 235-246

  Larbcharoensub, Noppadol ^a   Sornmayura, Pattana ^a   Sirachainan, Ekaphop ^a   Wilasrusmee, Chumpon ^b   Wanmoung, Harirak ^c   Janvilisri, Tavan ^d  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c THAMMASAT UNIVERSITY   (Thailand)

^d Mahidol University   (Thailand)

Author keywords

ABC transporter; Breast cancer resistance protein; Cholangiocarcinoma; Differentiation; Prognosis

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CELL; CHOLANGIOCYTE; DISEASE CLASSIFICATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INTRAHEPATIC BILE DUCT; INTRAHEPATIC CHOLANGIOCARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL;

ADULT; AGED; ATP-BINDING CASSETTE TRANSPORTERS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; SURVIVAL RATE; THAILAND; TUMOR MARKERS, BIOLOGICAL;

EID: 80052232659     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.03935.x     Document Type: Article

References (36)

1. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin. Liver Dis. 2004; 24; 115-125.
2. Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. H.P.B. 2008; 10; 77-82.
3. Patel T. Cholangiocarcinoma. Nat. Clin. Pract. Gastroenterol. Hepatol. 2006; 3; 33-42.
4. Jarnagin WR, Shoup M. Surgical management of cholangiocarcinoma. Semin. Liver Dis. 2004; 24; 189-199.
5. Malhi H, Gores GJ. Review article: the modern diagnosis and therapy of cholangiocarcinoma. Aliment. Pharmacol. Ther. 2006; 23; 1287-1296.
6. Endo I, Gonen M, Yopp AC et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann. Surg. 2008; 248; 84-96.
7. Higgins CF. ABC transporters: from microorganisms to man. Annu. Rev. Cell Biol. 1992; 8; 67-113.
8. Meier PJ, Stieger B. Bile salt transporters. Annu. Rev. Physiol. 2002; 64; 635-661.
9. Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008; 9; 105-127.
10. Gottesman MM. Mechanisms of cancer drug resistance. Annu. Rev. Med. 2002; 53; 615-627.
11. Steinbach D, Legrand O. ABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra? Leukemia 2007; 21; 1172-1176.
12. Munoz M, Henderson M, Haber M, Norris M. Role of the MRP1/ABCC1 multidrug transporter protein in cancer. IUBMB Life 2007; 59; 752-757.
13. Merino V, Jiménez-Torres NV, Merino-Sanjuán M. Relevance of multidrug resistance proteins on the clinical efficacy of cancer therapy. Curr. Drug Deliv. 2004; 1; 203-212.
14. Larbcharoensub N, Leopairat J, Sirachainan E et al. Association between multidrug resistance-associated protein 1 and poor prognosis in patients with nasopharyngeal carcinoma treated with radiotherapy and concurrent chemotherapy. Hum. Pathol. 2008; 39; 837-845.
15. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 1999; 39; 361-398.
16. Deeley RG, Cole SP. Substrate recognition and transport by multidrug resistance protein 1 (ABCC1). FEBS Lett. 2006; 580; 1103-1111.
17. Velamakanni S, Wei SL, Janvilisri T, van Veen HW. ABCG transporters: structure, substrate specificities and physiological roles: a brief overview. J. Bioenerg. Biomembr. 2007; 39; 465-471.
18. Janvilisri T, Venter H, Shahi S, Reuter G, Balakrishnan L, van Veen HW. Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J. Biol. Chem. 2003; 278; 20645-20651.
19. Janvilisri T, Shahi S, Venter H, Balakrishnan L, van Veen HW. Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). Biochem. J. 2005; 385; 419-426.
20. Chandra P, Brouwer KLR. The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharm. Res. 2004; 21; 719-735.
21. Wise C, Pilanthananond M, Perry BF, Alpini G, McNeal M, Glaser SS. Mechanisms of biliary carcinogenesis and growth. World J. Gastroenterol. 2008; 14; 2986-2989.
22. Rajagopal A, Simon SM. Subcellular localization and activity of multidrug resistance proteins. Mol. Biol. Cell 2003; 14; 3389-3399.
23. Kamata S, Kishimoto T, Kobayashi S, Miyazaki M. Expression and localization of ATP binding cassette (ABC) family of drug transporters in gastric hepatoid adenocarcinomas. Histopathology 2008; 52; 747-754.
24. Eid H, Mingfang L, Institoris E, Bodrogi I, Bak M. MRP expression of testicular cancers and its clinical relevance. Anticancer Res. 2000; 20; 4019-4022.
25. Aust S, Obrist P, Jaeger W et al. Subcellular localization of the ABCG2 transporter in normal and malignant human gallbladder epithelium. Lab. Invest. 2004; 84; 1024-1036.
26. Solazzo M, Fantappiè O, D'Amico M et al. Mitochondrial expression and functional activity of breast cancer resistance protein in different multiple drug-resistant cell lines. Cancer Res. 2009; 69; 7235-7242.
27. Lemos C, Kathmann I, Giovannetti E et al. Cellular folate status modulates the expression of BCRP and MRP multidrug transporters in cancer cell lines from different origins. Mol. Cancer Ther. 2009; 8; 655-664.
28. Bogert PT, LaRusso NF. Cholangiocyte biology. Curr. Opin. Gastroenterol. 2007; 23; 299-305.
29. Gupta N, Martin PM, Miyauchi S et al. Down-regulation of BCRP/ABCG2 in colorectal and cervical cancer. Biochem. Biophys. Res. Commun. 2006; 343; 571-577.
30. Berthiaume EP, Wands J. The molecular pathogenesis of cholangiocarcinoma. Semin. Liver Dis. 2004; 24; 127-137.
31. Alpini G, Baiocchi L, Glaser S et al. Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKC alpha. Hepatology 2002; 35; 1041-1052.
32. Sampson LK, Vickers SM, Ying W, Phillips JO. Tamoxifen-mediated growth inhibition of human cholangiocarcinoma. Cancer Res. 1997; 57; 1743-1749.
33. Imai Y, Ishikawa E, Asada S, Sugimoto Y. Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2. Cancer Res. 2005; 65; 596-604.
34. Roskams T. Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene 2006; 25; 3818-3822.
35. Krishnamurthy P, Schuetz JD. Role of ABCG2/BCRP in biology and medicine. Annu. Rev. Pharmacol. Toxicol. 2006; 46; 381-410.
36. Huls M, Russel FG, Masereeuw R. The role of ATP binding cassette transporters in tissue defense and organ regeneration. J. Pharmacol. Exp. Ther. 2009; 328; 3-9.